New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - oxaliplatin 50mg;   - powder for injection - 50 mg - active: oxaliplatin 50mg   excipient: lactose

Australia - English - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - oxaliplatin, quantity: 100 mg - injection, concentrated - excipient ingredients: nitrogen; water for injections - oxaliplatin is indicated for adjuvant treatment of stage iii (duke?s c) colon cancer, in combination with fluoropyrimidine agent.,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer.,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for the treatment of patients with advanced oesophagogastric cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - oxaliplatin, quantity: 50 mg - injection, concentrated - excipient ingredients: nitrogen; water for injections - oxaliplatin is indicated for adjuvant treatment of stage iii (duke?s c) colon cancer, in combination with fluoropyrimidine agent.,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer.,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for the treatment of patients with advanced oesophagogastric cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - oxaliplatin 50mg - powder for injection - 50 mg - active: oxaliplatin 50mg excipient: lactose - oxaliplatin, in combination with 5-fluorouracil and folinic acid, is indicated for: · adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - oxaliplatin 50mg;   - powder for infusion - 50 mg - active: oxaliplatin 50mg   excipient: lactose - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour;

Australia - English - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - oxaliplatin, quantity: 100 mg - injection, concentrated - excipient ingredients: water for injections; nitrogen - oxaliplatin is indicated for adjuvant treatment of stage iii (duke?s c) colon cancer, in combination with fluoropyrimidine agent.,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer.,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for the treatment of patients with advanced oesophagogastric cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - oxaliplatin, quantity: 50 mg - injection, concentrated - excipient ingredients: nitrogen; water for injections - oxaliplatin is indicated for adjuvant treatment of stage iii (duke?s c) colon cancer, in combination with fluoropyrimidine agent.,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer.,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for the treatment of patients with advanced oesophagogastric cancer.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - oxaliplatin - powder for solution for infusion - oxaliplatin 50 mg/vial - oxaliplatin - oxaliplatin - oxaliplatin in combination with 5-fluorouracil (5-fu) and folinic acid (fa) is indicated for: • adjuvant treatment of stage iii (duke‘s c) colon cancer after complete resection of primary tumor. • treatment of metastatic colorectal cancer. oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first-line treatment of patients with metastatic pancreatic adenocarcinoma (based on nccn guidelines, version 2.2014).

Israel - English - Ministry of Health

tzamal bio-pharma ltd - oxaliplatin - powder for solution for infusion - oxaliplatin 150 mg/vial - oxaliplatin - oxaliplatin - oxaliplatin in combination with 5-fluorouracil (5-fu) and folinic acid (fa) is indicated for: • adjuvant treatment of stage iii (duke‘s c) colon cancer after complete resection of primary tumor. • treatment of metastatic colorectal cancer. oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first-line treatment of patients with metastatic pancreatic adenocarcinoma (based on nccn guidelines, version 2.2014).

United States - English - NLM (National Library of Medicine)

app pharmaceuticals, llc - oxaliplatin (unii: 04zr38536j) (oxaliplatin - unii:04zr38536j) - oxaliplatin 50 mg in 10 ml - oxaliplatin, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for - adjuvant treatment of stage iii colon cancer in patients who have undergone complete resection of the primary tumor. - treatment of advanced colorectal cancer. oxaliplatin should not be administered to patients with a history of known allergy to oxaliplatin or other platinum compounds [see warnings and precautions (5.1)] . pregnancy category d based on direct interaction with dna, oxaliplatin may cause fetal harm when administered to a pregnant woman. there are no adequate and well-controlled studies of oxaliplatin in pregnant women. reproductive toxicity studies in rats demonstrated adverse effects on fertility and embryo-fetal development at maternal doses that were below the recommended human dose based on body surface area. if this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. women of childbeari